Idiopathic pulmonary fibrosis
Conditions
Interventions
Treatment group:Buyang Huanwu Decoction
Control group:Placebo
Sponsors
Affiliated Hospital of Chengdu University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: ? In line with the IPF diagnostic criteria set by the 2018 ATS/ERS/JRS/ALAT Diagnostic Guidelines: 1) HRCT showed common interstitial pneumonia: honeycombs with subpleural and basal lung distribution, with or without peripheral tractive bronchiectasis. 2) HRCT classification was probable or uncertain UIP, and histopathological classification was consistent with UIP: dense fibrosis with structural twist (i.e., destructive scar and/or honeycomb change), fibrosis mainly distributed subpleural and/or para-septal, patchy fibrosis involved in pulmonary parenchyma, and fibroblast foci; Or probably UIP Either 1) or 2) corresponds to pulmonary fibrosis; (2). In line with the TCM syndrome differentiation for qi stagnation and blood stasis syndrome: main symptoms: fatigue, fatigue, less qi lazy speech, cough and weak, phlegm white; Chest tightness, asthma, increased after activity, progressive, pulse heavy and astringent; Secondary symptoms: pale complexion, shortness of breath, palpitation and spontaneous sweating; Tongue image: the tongue is dark or petechiae, thin white or greasy white moss; Pulse: fine slow or fine astringent; ? The age range is 18-85; ? Patients voluntarily participated in the experiment and signed the informed consent
Exclusion criteria
Exclusion criteria: 1) Complicated with serious primary diseases of other systems, including malignant tumors, hematologic diseases, thyroid diseases, and serious cardiovascular and cerebrovascular diseases; He had a recent cardiovascular accident 2) Recent surgery that may have secondary bleeding events 3) Severe liver and kidney dysfunction 4) The presence of alcohol or drug abuse or dependence 5) Highly sensitive or allergic to prescribed drugs 6) Participants in other clinical studies in the last month taking other drugs that may interfere with the results 7) People with mental, intellectual, cognitive or language disabilities 8) Pregnant and lactating women 9) Those who are considered unsuitable to participate in the clinical trial by the researcher, including those who are judged by the researcher to have poor compliance or live far away from the subject and cannot follow up on schedule
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Therapeutic response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| TGF-ß1;Change in FVCfrom baseline;MMP9;KBILD score change value;HYP; | — |
Countries
China
Contacts
Public ContactFei Wang
Outcome results
None listed